109
total announcements
LINCOLN.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 10 Nov 2026
Market Cap
₹1,043 Cr
P/E (TTM)
10.6
EPS (TTM)
₹49.01
52W Low
₹439.95
52W High
₹770.00
Dividend Yield
0.35%
Beta
0.52
Price / Book
1.3
Return on Equity
12.69%
Debt / Equity
0.4
Revenue (TTM)
₹722 Cr
Gross Margin
50.74%
Operating Margin
10.35%
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced the resignation of Mr. Manoj Rai, Sr. General Manager- QA (Head QA), due to personal reasons, effective September 24, 2026.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced the closure of its trading window from October 1, 2026, till 48 hours after the declaration of its financial results for the quarter ended September 30, 2026. The company has informed its directors, senior management personnel, promoters, and connected persons not to trade in its securities during this period.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced the book closure and record date for its 32nd Annual General Meeting and final dividend for the financial year 2025-26. The final dividend is ₹ 1.80 per equity share, and the meeting is scheduled for September 30, 2026.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced the 32nd Annual General Meeting (AGM) scheduled for September 30, 2026, to determine the entitlement of members for payment of a final dividend of ₹ 1.80 per equity share, if approved.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has published a newspaper advertisement regarding its 32nd Annual General Meeting (AGM) to be held on September 30, 2026, through video conferencing.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced the unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has published the results in the Financial Express newspaper in English and Gujarati.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of ₹3,623.45 lakhs and earnings per share of ₹18.09.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with a net profit of ₹3,623.45 lakhs and earnings per share of ₹18.09.
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/08/2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.